Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

EMEA).

One-year findings from one of two ustekinumab Phase 3 trials were presented for the first time at the annual meeting of the American Academy of Dermatology this past Saturday, February 2.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)... , Aug. 27, 2014 ... report is available in its catalogue: ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... are materials that are readily decomposed by ... from conventional non-degradable packaging in terms of ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7MSC names Mary Beth Loesch President and CEO 2
... ... ... , ... OXFORD, England and LANGHORNE, Pennsylvania, ...
... ... ... , ... ...
... , ... ... ... ...
Cached Biology Technology:EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 2EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 3EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 2Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 3Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 5Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 6Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 7MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 2MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 3MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 4
(Date:8/27/2014)... 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... in the offering consists of 2,000 shares of common ...
(Date:8/27/2014)... of North America,s megafauna mastodons, short-faced bears, giant ... disappeared close to 13,000 years ago at the ... massive extinction has long been debated by scientists who, ... A group of scientists, including UC Santa Barbara,s James ... posited that a comet collision with Earth played a ...
(Date:8/27/2014)... of the human genome was unveiled today in the ... comparison yet of how the genomes of the fruit ... appearing August 28 in in the journal Nature ... species, genomes is "read out," and how their DNA ... add billions of entries to a publicly available archive ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... arrhythmias are killers. They strike without ... about 10 percent of all deaths in the ... molecular mechanism associated with arrhythmias. Their findings, reported ... could lead to novel arrhythmia treatments., "The current ...
... expedition in 1965 to trap moths on Mount Kinabalu in ... groundwork for a study of the impacts of climate change. ... has repeated the survey 42 years later, and found that, ... over the intervening years to cope with changes in climate. ...
... and food research, is coordinating the international TXOTX ... fundamental aim of this project is to collate ... programs from the different regions in the world,s ... cooperation between countries, regional fisheries organisations and other ...
Cached Biology News:Studies point to novel target for treating arrhythmias 2Studies point to novel target for treating arrhythmias 3The global impact of climate change on biodiversity 2TXOTX, coordinated international project to contribute to sustainability of the marine resources 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Biology Products: